{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:29:40Z","timestamp":1790897380249,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR070251"],"award-info":[{"award-number":["RS-2022-NR070251"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2023-KH141546"],"award-info":[{"award-number":["RS-2023-KH141546"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01600-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:02:53Z","timestamp":1766062973000},"page":"763-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Pathophysiology and Therapeutic Paradigm Shifts in Chronic Spontaneous Urticaria: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-7505","authenticated-orcid":false,"given":"Han B.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-199X","authenticated-orcid":false,"given":"Ji Y.","family":"Um","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2795-0140","authenticated-orcid":false,"given":"Bo Y.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-8668","authenticated-orcid":false,"given":"Chun W.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5846-0008","authenticated-orcid":false,"given":"Hye O.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bonnekoh H, Metz M, Maurer M. Chronic spontaneous urticaria: a review. JAMA. 2024;332:1464\u201377. https:\/\/doi.org\/10.1001\/jama.2024.15568.","journal-title":"JAMA"},{"key":"1600_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/all.12380","volume":"69","author":"M Cicardi","year":"2014","unstructured":"Cicardi M, Aberer W, Banerji A, et\u00a0al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602\u201316. https:\/\/doi.org\/10.1111\/all.12380.","journal-title":"Allergy"},{"key":"1600_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12016-022-08952-y","volume":"63","author":"B Greiner","year":"2022","unstructured":"Greiner B, Nicks S, Adame M, McCracken J. Pathophysiology, diagnosis, and management of chronic spontaneous urticaria: a literature review. Clin Rev Allergy Immunol. 2022;63:381\u20139. https:\/\/doi.org\/10.1007\/s12016-022-08952-y.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1600_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jaci.2022.12.809","volume":"151","author":"C Seg\u00fa-Verg\u00e9s","year":"2023","unstructured":"Seg\u00fa-Verg\u00e9s C, G\u00f3mez J, Terradas-Montana P, et\u00a0al. Unveiling chronic spontaneous urticaria pathophysiology through systems biology. J Allergy Clin Immunol. 2023;151:1005\u201314. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.809.","journal-title":"J Allergy Clin Immunol"},{"key":"1600_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/all.15603","volume":"78","author":"A Kaplan","year":"2023","unstructured":"Kaplan A, Lebwohl M, Gim\u00e9nez-Arnau AM, et\u00a0al. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78:389\u2013401. https:\/\/doi.org\/10.1111\/all.15603.","journal-title":"Allergy"},{"key":"1600_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100533","volume":"14","author":"M S\u00e1nchez-Borges","year":"2021","unstructured":"S\u00e1nchez-Borges M, Ansotegui IJ, Baiardini I, et\u00a0al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14:100533. https:\/\/doi.org\/10.1016\/j.waojou.2021.100533.","journal-title":"World Allergy Organ J"},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.jaip.2023.02.022","volume":"11","author":"R Asero","year":"2023","unstructured":"Asero R, Ferrer M, Kocat\u00fcrk E, Maurer M. Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity, and autoallergy. J Allergy Clin Immunol Pract. 2023;11:2302\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.022.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1600_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/2040622315603951","volume":"6","author":"C Vestergaard","year":"2015","unstructured":"Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis. 2015;6:304\u201313. https:\/\/doi.org\/10.1177\/2040622315603951.","journal-title":"Ther Adv Chronic Dis"},{"key":"1600_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/ACI.0000000000000927","volume":"23","author":"YK Xiang","year":"2023","unstructured":"Xiang YK, Guloglu S, Elieh-Ali-Komi D, Kocat\u00fcrk E. Chronic spontaneous urticaria: new evidences on the role of autoimmunity. Curr Opin Allergy Clin Immunol. 2023;23:438\u201345. https:\/\/doi.org\/10.1097\/ACI.0000000000000927.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1600_CR10","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.jaip.2024.04.027","volume":"12","author":"P Pyatilova","year":"2024","unstructured":"Pyatilova P, Hackler Y, Aulenbacher F, et\u00a0al. Non-skin related symptoms are common in chronic spontaneous urticaria and linked to active and uncontrolled disease: results from the Chronic Urticaria Registry. J Allergy Clin Immunol Pract. 2024;12:1890-9.e3. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.027.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/cea.12673","volume":"46","author":"P Kolkhir","year":"2016","unstructured":"Kolkhir P, Pogorelov D, Olisova O, Maurer M. Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus-a systematic review. Clin Exp Allergy. 2016;46:275\u201387. https:\/\/doi.org\/10.1111\/cea.12673.","journal-title":"Clin Exp Allergy"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1586\/1744666X.2016.1127160","volume":"12","author":"R Asero","year":"2016","unstructured":"Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic spontaneous urticaria: immune system, blood coagulation, and more. Expert Rev Clin Immunol. 2016;12:229\u201331. https:\/\/doi.org\/10.1586\/1744666X.2016.1127160.","journal-title":"Expert Rev Clin Immunol"},{"key":"1600_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/jdv.19940","volume":"38","author":"M Maurer","year":"2024","unstructured":"Maurer M, Augustin M, Bauer S, et\u00a0al. Modelling of patient journey in chronic spontaneous urticaria: increasing awareness and education by shorten patients\u2019 disease journey in Germany. J Eur Acad Dermatol Venereol. 2024;38:2093\u2013101. https:\/\/doi.org\/10.1111\/jdv.19940.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1600_CR14","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","volume":"11","author":"YK Xiang","year":"2023","unstructured":"Xiang YK, Kolkhir P, Scheffel J, et\u00a0al. Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. J Allergy Clin Immunol Pract. 2023;11:2417-25.e1. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.006.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1600_CR15","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.jaip.2021.03.033","volume":"9","author":"AM Gim\u00e9nez-Arnau","year":"2021","unstructured":"Gim\u00e9nez-Arnau AM, DeMontojoye L, Asero R, et\u00a0al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9:2195\u2013208. https:\/\/doi.org\/10.1016\/j.jaip.2021.03.033.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1600_CR16","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3390\/cells10112906","volume":"10","author":"H Ogasawara","year":"2021","unstructured":"Ogasawara H, Noguchi M. Therapeutic potential of MRGPRX2 inhibitors on mast cells. Cells. 2021;10:2906. https:\/\/doi.org\/10.3390\/cells10112906.","journal-title":"Cells"},{"key":"1600_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature14022","volume":"519","author":"BD McNeil","year":"2015","unstructured":"McNeil BD, Pundir P, Meeker S, et\u00a0al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519:237\u201341. https:\/\/doi.org\/10.1038\/nature14022.","journal-title":"Nature"},{"key":"1600_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Gim\u00e9nez-Arnau AM, Kulthanan K, et\u00a0al. Urticaria. Nat Rev Dis Prim. 2022;8:61. https:\/\/doi.org\/10.1038\/s41572-022-00389-z.","journal-title":"Nat Rev Dis Prim"},{"key":"1600_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et\u00a0al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"key":"1600_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, et\u00a0al. Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN Task Force report. Allergy. 2011;66:317\u201330. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02496.x.","journal-title":"Allergy"},{"key":"1600_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.iac.2024.03.004","volume":"44","author":"L Keller","year":"2024","unstructured":"Keller L, Stitt J. Chronic spontaneous urticaria: quality of life and economic impacts. Immunol Allergy Clin North Am. 2024;44:453\u201367. https:\/\/doi.org\/10.1016\/j.iac.2024.03.004.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1600_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000358614","volume":"100","author":"M Maurer","year":"2014","unstructured":"Maurer M. Urticaria and angioedema. Chem Immunol Allergy. 2014;100:101\u20134. https:\/\/doi.org\/10.1159\/000358614.","journal-title":"Chem Immunol Allergy"},{"issue":"2","key":"1600_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/jdv.14584","volume":"32","author":"MM Balp","year":"2018","unstructured":"Balp MM, Khalil S, Tian H, et\u00a0al. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2018;32(2):282\u201390. https:\/\/doi.org\/10.1111\/jdv.14584.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1600_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13601-016-0120-0","volume":"6","author":"AM Gimen\u00e9z-Arnau","year":"2016","unstructured":"Gimen\u00e9z-Arnau AM, Spector S, Antonova E, et\u00a0al. Improvement of sleep in patients with chronic idiopathic\/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy. 2016;6:32. https:\/\/doi.org\/10.1186\/s13601-016-0120-0.","journal-title":"Clin Transl Allergy"},{"key":"1600_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317499","volume":"20","author":"NTT My","year":"2025","unstructured":"My NTT, My LH, Minh VN, et\u00a0al. Factors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population. PLoS ONE. 2025;20:e0317499. https:\/\/doi.org\/10.1371\/journal.pone.0317499.","journal-title":"PLoS ONE"},{"issue":"2","key":"1600_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","volume":"136","author":"BF O'Donnell","year":"1997","unstructured":"O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197\u2013201.","journal-title":"Br J Dermatol."},{"key":"1600_CR27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","volume":"153","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Maurer M, Saini SS. BTK signaling\u2014A crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153:1229\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.008.","journal-title":"J Allergy Clin Immunol"},{"key":"1600_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13555-025-01348-8","volume":"15","author":"K Weller","year":"2025","unstructured":"Weller K, Winders T, McCarthy J, et\u00a0al. Urticaria voices: real-world experience of patients living with chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2025;15:747\u201361. https:\/\/doi.org\/10.1007\/s13555-025-01348-8.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1600_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40359-023-01284-2","volume":"11","author":"J Donnelly","year":"2023","unstructured":"Donnelly J, Ridge K, O\u2019Donovan R, Conlon N, Dunne PJ. Psychosocial factors and chronic spontaneous urticaria: a systematic review. BMC Psychol. 2023;11:239. https:\/\/doi.org\/10.1186\/s40359-023-01284-2.","journal-title":"BMC Psychol"},{"key":"1600_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s40521-024-00375-8","volume":"11","author":"YK Xiang","year":"2024","unstructured":"Xiang YK, T\u00fcrk M, Ojeda IC, et\u00a0al. Psychological stress and urticaria: pathophysiologic and therapeutic updates. Curr Treat Options Allergy. 2024;11:194\u2013210. https:\/\/doi.org\/10.1007\/s40521-024-00375-8.","journal-title":"Curr Treat Options Allergy"},{"key":"1600_CR31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81443","volume":"17","author":"GN Konstantinou","year":"2025","unstructured":"Konstantinou GN, Podder I, Konstantinou G. Mental health interventions in refractory chronic spontaneous urticaria: a call to expand treatment guidelines. Cureus. 2025;17:e81443. https:\/\/doi.org\/10.7759\/cureus.81443.","journal-title":"Cureus"},{"key":"1600_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14744\/SEMB.2024.54871","volume":"59","author":"PO Cetinkaya","year":"2025","unstructured":"Cetinkaya PO, Kurt BO, Aktaran A, Aksu A, Altunay IK. Sleep disturbance and psychological stress: two interconnected conditions in chronic spontaneous urticaria. Sisli Etfal Hastan Tip Bul. 2025;59:35\u201343. https:\/\/doi.org\/10.14744\/SEMB.2024.54871.","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"1600_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011992","volume":"97","author":"GY He","year":"2018","unstructured":"He GY, Tsai TF, Lin CL, Shih HM, Hsu TY. Association between sleep disorders and subsequent chronic spontaneous urticaria development: a population-based cohort study. Medicine (Baltimore). 2018;97:e11992. https:\/\/doi.org\/10.1097\/MD.0000000000011992.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14656566.2024.2345731","volume":"25","author":"YK Xiang","year":"2024","unstructured":"Xiang YK, Fok JS, Podder I, et\u00a0al. An update on the use of antihistamines in managing chronic urticaria. Expert Opin Pharmacother. 2024;25(5):551\u201369. https:\/\/doi.org\/10.1080\/14656566.2024.2345731.","journal-title":"Expert Opin Pharmacother"},{"key":"1600_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-084987","volume":"15","author":"DG Zhang","year":"2025","unstructured":"Zhang DG, S\u00f8rensen JA, Ghazanfar MN, et\u00a0al. Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial. BMJ Open. 2025;15:e084987. https:\/\/doi.org\/10.1136\/bmjopen-2024-084987.","journal-title":"BMJ Open"},{"key":"1600_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","volume":"85","author":"P Kolkhir","year":"2025","unstructured":"Kolkhir P, Fok JS, Kocat\u00fcrk E, et\u00a0al. Update on the treatment of chronic spontaneous urticaria. Drugs. 2025;85:475\u201386. https:\/\/doi.org\/10.1007\/s40265-025-02170-4.","journal-title":"Drugs"},{"key":"1600_CR37","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guill\u00e9n-Aguinaga","year":"2016","unstructured":"Guill\u00e9n-Aguinaga S, Presa IJ, Aguinaga-Ontoso E, Guill\u00e9n-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175:1153\u201365. https:\/\/doi.org\/10.1111\/bjd.14768.","journal-title":"Br J Dermatol"},{"key":"1600_CR38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000246281","volume":"193","author":"T Zuberbier","year":"1996","unstructured":"Zuberbier T, M\u00fcnzberger C, Haustein U, et\u00a0al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193:324\u20137. https:\/\/doi.org\/10.1159\/000246281.","journal-title":"Dermatology"},{"key":"1600_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023","volume":"57","author":"H Sofen","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, et\u00a0al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023;57:101826. https:\/\/doi.org\/10.1016\/j.eclinm.2023.","journal-title":"EClinicalMedicine"},{"key":"1600_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.994823","volume":"13","author":"D Matsubara","year":"2022","unstructured":"Matsubara D, Yanase Y, Ishii K, et\u00a0al. Basophils activation of patients with chronic spontaneous urticaria in response to C5a despite failure to respond to IgE-mediated stimuli. Front Immunol. 2022;13:994823. https:\/\/doi.org\/10.3389\/fimmu.2022.994823.","journal-title":"Front Immunol"},{"key":"1600_CR41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1159\/000521900","volume":"183","author":"P Zhou","year":"2022","unstructured":"Zhou P, Zeng S, Fu L, Chen H, Li L. Efficacy and safety of intensive nonsedating antihistamines for chronic spontaneous urticaria: a meta-analysis of randomized controlled trials. Int Arch Allergy Immunol. 2022;183:796\u2013803. https:\/\/doi.org\/10.1159\/000521900.","journal-title":"Int Arch Allergy Immunol"},{"key":"1600_CR42","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","volume":"149","author":"S Altrichter","year":"2022","unstructured":"Altrichter S, Staubach P, Pasha M, et\u00a0al. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol. 2022;149:1683-90.e7. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.772.","journal-title":"J Allergy Clin Immunol"},{"key":"1600_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","volume":"403","author":"M Maurer","year":"2024","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, et\u00a0al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. 2024;403:147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","journal-title":"Lancet"},{"key":"1600_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","volume":"11","author":"P Gasser","year":"2020","unstructured":"Gasser P, Tarchevskaya SS, Guntern P, et\u00a0al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11:165. https:\/\/doi.org\/10.1038\/s41467-019-13815-w.","journal-title":"Nat Commun"},{"key":"1600_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13946","volume":"33","author":"I Podder","year":"2020","unstructured":"Podder I, Das A, Ghosh S, et\u00a0al. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: a double-blind, parallel group, randomized controlled trial. Dermatol Ther. 2020;33:e13946. https:\/\/doi.org\/10.1111\/dth.13946.","journal-title":"Dermatol Ther"},{"key":"1600_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5125\/jkaoms.2023.49.6.311","volume":"49","author":"H Lee","year":"2023","unstructured":"Lee H, Myoung H, Kim SM. Review of two immunosuppressants: tacrolimus and cyclosporine. J Korean Assoc Oral Maxillofac Surg. 2023;49:311\u201323. https:\/\/doi.org\/10.5125\/jkaoms.2023.49.6.311.","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"1600_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13223-023-00820-4","volume":"19","author":"AF LaCava","year":"2023","unstructured":"LaCava AF, Fadugba OO. Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases. Allergy Asthma Clin Immunol. 2023;19:78. https:\/\/doi.org\/10.1186\/s13223-023-00820-4.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1600_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ijd.17358","volume":"64","author":"L Mateu-Arrom","year":"2025","unstructured":"Mateu-Arrom L, Gim\u00e9nez-Arnau AM, Exp\u00f3sito-Serrano V, et\u00a0al. Cyclosporine for the treatment of chronic spontaneous urticaria refractory to antihistamines and omalizumab: a case series. Int J Dermatol. 2025;64:219\u201320. https:\/\/doi.org\/10.1111\/ijd.17358.","journal-title":"Int J Dermatol"},{"key":"1600_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110577","volume":"123","author":"W Bei","year":"2023","unstructured":"Bei W, Qian J, Zilu Q, et\u00a0al. Comparing four immunosuppressive agents for chronic spontaneous urticaria-a network meta-analysis. Int Immunopharmacol. 2023;123:110577. https:\/\/doi.org\/10.1016\/j.intimp.2023.110577.","journal-title":"Int Immunopharmacol"},{"key":"1600_CR50","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","volume":"149","author":"M Tsai","year":"2022","unstructured":"Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol. 2022;149:1845\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.012.","journal-title":"J Allergy Clin Immunol"},{"key":"1600_CR51","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.7150\/thno.46719","volume":"10","author":"P Valent","year":"2020","unstructured":"Valent P, Akin C, Hartmann K, et\u00a0al. Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich\u2019s visions to precision medicine concepts. Theranostics. 2020;10:10743\u201368. https:\/\/doi.org\/10.7150\/thno.46719.","journal-title":"Theranostics"},{"key":"1600_CR52","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, et\u00a0al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046\u201351. https:\/\/doi.org\/10.1038\/nbt.1990.","journal-title":"Nat Biotechnol"},{"key":"1600_CR53","unstructured":"Celldex Therapeutics. Celldex presents data demonstrating profound long-term improvement in angioedema in Barzolvolimab Phase 2 study in chronic spontaneous urticaria at EAACI 2025. 2025 [cited 2025 Aug 7]. https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-presents-data-demonstrating-profound-long-term."},{"key":"1600_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111499","volume":"17","author":"R Asero","year":"2024","unstructured":"Asero R, Calzari P, Vaienti S, Cugno M. Therapies for chronic spontaneous urticaria: present and future developments. Pharmaceuticals (Basel). 2024;17:1499. https:\/\/doi.org\/10.3390\/ph17111499.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1600_CR55","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","volume":"161","author":"A Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau A, Ferrucci S, Ben-Shoshan M, et\u00a0al. Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial. JAMA Dermatol. 2025;161:679\u201387. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0733.","journal-title":"JAMA Dermatol"},{"key":"1600_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15932","volume":"35","author":"P Mansouri","year":"2022","unstructured":"Mansouri P, Mozafari N, Chalangari R, Martits-Chalangari K. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther. 2022;35:e15932. https:\/\/doi.org\/10.1111\/dth.15932.","journal-title":"Dermatol Ther"},{"key":"1600_CR57","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005.","journal-title":"J Am Acad Dermatol"},{"key":"1600_CR58","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2340\/00015555-3006","volume":"98","author":"A Fukunaga","year":"2018","unstructured":"Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol. 2018;98:904\u20135. https:\/\/doi.org\/10.2340\/00015555-3006.","journal-title":"Acta Derm Venereol"},{"key":"1600_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et\u00a0al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2.","journal-title":"Arthritis Res Ther"},{"key":"1600_CR60","unstructured":"FDA Drug Safety Communication. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. U.S. Food and Drug Administration. 2019."},{"key":"1600_CR61","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009.","journal-title":"J Allergy Clin Immunol"},{"key":"1600_CR62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et\u00a0al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154:184\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"key":"1600_CR63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40257-023-00761-z","volume":"24","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Fox L, Siebenhaar F, Metz M, Maurer M. Stepping down treatment in chronic spontaneous urticaria: what we know and what we don\u2019t know. Am J Clin Dermatol. 2023;24:397\u2013404. https:\/\/doi.org\/10.1007\/s40257-023-00761-z.","journal-title":"Am J Clin Dermatol"},{"key":"1600_CR64","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/cea.13616","volume":"50","author":"DA Sabag","year":"2020","unstructured":"Sabag DA, Matanes L, Bejar J, et\u00a0al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020;50:799\u2013804. https:\/\/doi.org\/10.1111\/cea.13616.","journal-title":"Clin Exp Allergy"},{"key":"1600_CR65","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jaip.2023.05.019","volume":"11","author":"H Bonnekoh","year":"2023","unstructured":"Bonnekoh H, Kiefer L, Buttgereit T, et\u00a0al. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: a case series. J Allergy Clin Immunol Pract. 2023;11:2578-80.e1. https:\/\/doi.org\/10.1016\/j.jaip.2023.05.019.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1600_CR66","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12016-021-08886-x","volume":"61","author":"L He","year":"2021","unstructured":"He L, Yi W, Huang X, Long H, Lu Q. Chronic urticaria: advances in understanding of the disease and clinical management. Clin Rev Allergy Immunol. 2021;61:424\u201348. https:\/\/doi.org\/10.1007\/s12016-021-08886-x.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1600_CR67","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/bjd.13621","volume":"172","author":"AB Kay","year":"2015","unstructured":"Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (\u201cidiopathic\u201d) urticaria. Br J Dermatol. 2015;172:1294\u2013302. https:\/\/doi.org\/10.1111\/bjd.13621.","journal-title":"Br J Dermatol"},{"key":"1600_CR68","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/cells13030220","volume":"13","author":"L Lerner","year":"2024","unstructured":"Lerner L, Babina M, Zuberbier T, Stevanovic K. Beyond allergies-updates on the role of Mas-related G-protein-coupled receptor X2 in chronic urticaria and atopic dermatitis. Cells. 2024;13:220. https:\/\/doi.org\/10.3390\/cells13030220.","journal-title":"Cells"},{"issue":"2","key":"1600_CR69","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/0378-6323.93629","volume":"78","author":"N Pazyar","year":"2012","unstructured":"Pazyar N, Yaghoobi R, Kazerouni A, Feily A. Oatmeal in dermatology: a brief review. Indian J Dermatol Venereol Leprol. 2012;78(2):142\u20135.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1600_CR70","doi-asserted-by":"publisher","DOI":"10.4161\/derm.29727","volume":"6","author":"T Boonpiyathad","year":"2014","unstructured":"Boonpiyathad T, Pradubpongsa P, Sangasapaviriya A. Vitamin d supplements improve urticaria symptoms and quality of life in chronic spontaneous urticaria patients: a prospective case-control study. Dermatoendocrinol. 2014;6:e29727. https:\/\/doi.org\/10.4161\/derm.29727.","journal-title":"Dermatoendocrinol"},{"key":"1600_CR71","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-020-00461-x","volume":"16","author":"MM Wong","year":"2020","unstructured":"Wong MM, Keith PK. Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review. Allergy Asthma Clin Immunol. 2020;16:72. https:\/\/doi.org\/10.1186\/s13223-020-00461-x.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01600-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:40:54Z","timestamp":1772001654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01600-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Han B. Kim has nothing to disclose. Ji Y. Um has nothing to disclose. Bo Y. Chung has nothing to disclose. Chun W. Park has nothing to disclose. Hye O. Kim has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}